Kernel Assisted Learning for Personalized Dose Finding
Liangyu Zhu, Wenbin Lu, Michael R. Kosorok, Rui Song
摘要
An individualized dose rule recommends a dose level within a continuous safe dose range based on patient level information such as physical conditions, genetic factors and medication histories. Traditionally, personalized dose finding process requires repeating clinical visits of the patient and frequent adjustments of the dosage. Thus the patient is constantly exposed to the risk of underdosing and overdosing during the process. Statistical methods for finding an optimal individualized dose rule can lower the costs and risks for patients. In this article, we propose a kernel assisted learning method for estimating the optimal individualized dose rule. The proposed methodology can also be applied to all other continuous decision-making problems. Advantages of the proposed method include robustness to model misspecification and capability of providing statistical inference for the estimated parameters. In the simulation studies, we show that this method is capable of identifying the optimal individualized dose rule and produces favorable expected outcomes in the population. Finally, we illustrate our approach using data from a warfarin dosing study for thrombosis patients.
问问这篇 Paper
智能体会读完全文。
Lune 把这篇 Paper 索引到了最后一个公式,引用它的顶会 Paper 也一样。你提问,回答直接引用原文。
引用它的顶会 Paper1
问问它们各自怎么用它相关 Paper
- Quasi-optimal Reinforcement Learning with Continuous ActionsYuhan Li, Wenzhuo Zhou, Ruoqing ZhuICLR 2023 · 被引用 2 次
- ESCADA: Efficient Safety and Context Aware Dose Allocation for Precision MedicineIlker Demirel, Ahmet Alparslan Celik, Cem TekinNeurIPS 2022 · 被引用 6 次
- Reliable Off-Policy Learning for Dosage CombinationsJonas Schweisthal, Dennis Frauen, Valentyn Melnychuk, Stefan FeuerriegelNeurIPS 2023 · 被引用 22 次
- Learning Individualized Treatment Rules with Many Treatments: A Supervised Clustering Approach Using Adaptive FusionHaixu Ma, Donglin Zeng, Yufeng LiuNeurIPS 2022 · 被引用 22 次
- Safe Exploration in Dose Finding Clinical Trials with Heterogeneous ParticipantsIsabel Chien, Wessel P. Bruinsma, Javier González Hernández, Richard E. TurnerICML 2024
